COMMUNIQUÉS West-GlobeNewswire

Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.

04/10/2019 - 14:04

SOUTH EASTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based [...]

Cynata Advances Toward Phase 2 Clinical Trial of Cymerus(TM) MSCs in Patients with Osteoarthritis

04/10/2019 - 14:05

MELBOURNE, Australia, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to provide an update on start-up [...]

Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

04/10/2019 - 14:30

NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, [...]

Assure Holdings Announces Issuance of Options Under Stock Option Plan

04/10/2019 - 14:30

Company Appoints Scott Kozak as Director of Investor and Media Relations DENVER, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCQB: ARHH), a provider of [...]

Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Highlight Camelina Platform for Producing PHB Biomaterials to Improve Water Quality at International Scientific Conference

04/10/2019 - 14:30

WOBURN, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food [...]

Conformis Announces Departure of Paul Weiner, CFO

04/10/2019 - 14:30

BILLERICA, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell [...]

Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

04/10/2019 - 14:31

-- Improvements on functional measures seen in all three participants -- -- Significant reduction in creatine kinase maintained over nine months -- -- Results follow positive and robust expression and biomarker data [...]

Pixium Vision apporte des précisions sur la participation de Omnes Capital, inchangée depuis fin 2017

04/10/2019 - 15:49

Paris, 4 octobre 2019 – 15:30 CEST - Pixium Vision (FR0011950641 - PIX), société bioélectronique qui développe des systèmes de vision bionique innovants pour permettre aux patients ayant perdu la vue de vivre de façon [...]

Pixium Vision provides clarification on Omnes Capital shareholding, unchanged since end 2017

04/10/2019 - 16:17

Paris, 4 October 2019 – 16:00 CEST - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, [...]

DBV Technologies annonce l'acceptation par la FDA du dépôt de sa demande de sa Licence Biologique pour Viaskin Peanut, un traitement de l'allergie aux arachides

04/10/2019 - 17:45

Montrouge, France, le 4 octobre (17 h 30 CEST) 2019 DBV Technologies annonce l'acceptation par la FDA du dépôt de sa demande de sa Licence Biologique pour Viaskin Peanut, un traitement de l'allergie aux arachides Si [...]

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy

04/10/2019 - 17:45

Montrouge, France, October 4, 2019 DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy If approved, Viaskin Peanut would be the first and only epicutaneous [...]

Press news Biocartis Group NV: Disclosure of a transparency notification

04/10/2019 - 07:00

PRESS RELEASE : REGULATED INFORMATION 4 October 2019, 7:00 CEST Disclosure of a transparency notification Mechelen, Belgium, 4 October 2019 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular [...]

Statement re: Appointment of Corporate Broker

04/10/2019 - 08:00

DXS INTERNATIONAL PLC Appointment of Corporate Broker The Board of DXS International plc (“the Company”), the NEX Growth Market quoted healthcare information and digital clinical decision support systems provider, is [...]

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

04/10/2019 - 08:39

LONDON, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor [...]

Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD

04/10/2019 - 10:30

Data presented in an oral presentation at World Muscle Society meeting highlighted safety, tolerability, pharmacokinetics and target engagement of losmapimod in patients with facioscapulohumeral dystrophy. CAMBRIDGE, [...]

NOTICE TO DISREGARD – Dabir Surfaces

04/10/2019 - 04:01

CHICAGO, Oct. 03, 2019 (GLOBE NEWSWIRE) -- We are advised by Dabir Surfaces that journalists and other readers should disregard the news release, “Dabir Surfaces Inc. Announces Master Product Agreement with Trinity [...]

Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

03/10/2019 - 22:01

NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, [...]

Entasis Therapeutics Announces Multiple Presentations at ID Week 2019

03/10/2019 - 22:01

CEO Dr. Manos Perros participated in Industry Panel today WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel [...]

Aptevo Therapeutics Provides Corporate and Pipeline Update

03/10/2019 - 22:02

Reports Record Quarterly IXINITY ® Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study; Evidence of Potential Clinical Activity [...]